Gilead Sciences Inc
GILD112.100USD
+1.110+1.00%
Handelsschluss 09/26, 16:00（ET）Kurse um 15 Minuten verzögert
139.23BMarktkapitalisierung
22.06KGV TTM
mehr Informationen über Gilead Sciences Inc Unternehmen
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
Unternehmensinformationen
BörsenkürzelGILD
Name des UnternehmensGilead Sciences Inc
IPO-datumJan 22, 1992
CEOMr. Daniel P. O'Day
Anzahl der mitarbeiter17600
WertpapierartOrdinary Share
GeschäftsjahresendeJan 22
Addresse333 Lakeside Dr
StadtFOSTER CITY
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94404-1147
Telefon16505743000
Websitehttps://www.gilead.com/
BörsenkürzelGILD
IPO-datumJan 22, 1992
CEOMr. Daniel P. O'Day
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
85.97K
-1.12%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
26.39K
+2.65%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Erin Burkhart
Ms. Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Senior Vice President, Principal Accounting Officer, Controller
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
85.97K
-1.12%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Executive Vice President - Corporate Affairs, General Counsel
Executive Vice President - Corporate Affairs, General Counsel
26.39K
+2.65%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Erin Burkhart
Ms. Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Senior Vice President, Principal Accounting Officer, Controller
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biktarvy
3.15B
47.25%
Descovy
586.00M
8.79%
Yescarta
386.00M
5.79%
Genvoya
364.00M
5.46%
Sofosbuvir/Velpatasvir
345.00M
5.17%
Andere
1.84B
27.54%
Nach RegionUSD
Name
Umsatz
Anteil
United States
4.47B
67.02%
Europe
1.06B
15.94%
Other Locations
829.00M
12.43%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biktarvy
3.15B
47.25%
Descovy
586.00M
8.79%
Yescarta
386.00M
5.79%
Genvoya
364.00M
5.46%
Sofosbuvir/Velpatasvir
345.00M
5.17%
Andere
1.84B
27.54%
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.57%
BlackRock Institutional Trust Company, N.A.
5.71%
State Street Global Advisors (US)
4.77%
Fidelity Management & Research Company LLC
4.33%
Capital World Investors
3.73%
Andere
71.89%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.57%
BlackRock Institutional Trust Company, N.A.
5.71%
State Street Global Advisors (US)
4.77%
Fidelity Management & Research Company LLC
4.33%
Capital World Investors
3.73%
Andere
71.89%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
52.78%
Investment Advisor/Hedge Fund
26.40%
Pension Fund
2.96%
Research Firm
2.61%
Hedge Fund
2.24%
Bank and Trust
1.83%
Sovereign Wealth Fund
1.71%
Insurance Company
0.13%
Venture Capital
0.10%
Andere
9.22%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
3388
1.12B
90.01%
-12.02M
2025Q1
3442
1.12B
90.14%
-10.49M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
2023Q1
3195
1.09B
87.26%
-11.17M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
116.91M
9.4%
+1.94M
+1.69%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
70.66M
5.68%
-3.80M
-5.11%
Mar 31, 2025
State Street Global Advisors (US)
59.52M
4.79%
-858.08K
-1.42%
Mar 31, 2025
Fidelity Management & Research Company LLC
51.21M
4.12%
+16.57M
+47.83%
Mar 31, 2025
Capital World Investors
53.55M
4.3%
-18.16M
-25.32%
Mar 31, 2025
Wellington Management Company, LLP
27.36M
2.2%
-8.30M
-23.28%
Mar 31, 2025
Capital Research Global Investors
54.61M
4.39%
-3.34M
-5.76%
Mar 31, 2025
Dodge & Cox
32.69M
2.63%
-252.93K
-0.77%
Mar 31, 2025
Geode Capital Management, L.L.C.
28.48M
2.29%
+190.23K
+0.67%
Mar 31, 2025
Invesco Capital Management (QQQ Trust)
25.70M
2.07%
-130.67K
-0.51%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
VanEck Biotech ETF
13.21%
iShares Biotechnology ETF
6.83%
Invesco Biotechnology & Genome ETF
5.14%
Invesco Pharmaceuticals ETF
5.03%
Simplify Health Care ETF
4.44%
TBG Dividend Focus ETF
3.88%
First Trust NYSE Arca Biotechnology Index Fund
3.52%
iShares U.S. Healthcare ETF
2.85%
Health Care Select Sector SPDR Fund
2.79%
WisdomTree U.S. High Dividend Fund
2.74%
Mehr Anzeigen
VanEck Biotech ETF
Anteil13.21%
iShares Biotechnology ETF
Anteil6.83%
Invesco Biotechnology & Genome ETF
Anteil5.14%
Invesco Pharmaceuticals ETF
Anteil5.03%
Simplify Health Care ETF
Anteil4.44%
TBG Dividend Focus ETF
Anteil3.88%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.52%
iShares U.S. Healthcare ETF
Anteil2.85%
Health Care Select Sector SPDR Fund
Anteil2.79%
WisdomTree U.S. High Dividend Fund
Anteil2.74%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
18.49B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
Apr 28, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Jun 29, 2023 going ex on Jun 14, 2023
Jun 15, 2023
Jun 29, 2023
Jun 14, 2023
Feb 02, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Mar 30, 2023 going ex on Mar 14, 2023
Mar 15, 2023
Mar 30, 2023
Mar 14, 2023
Oct 27, 2022
GILD.NB Final Cash Dividend of gross USD 0.73 paid on Dec 29, 2022 going ex on Dec 14, 2022
Dec 15, 2022
Dec 29, 2022
Dec 14, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
